AimThe importance of human papillomavirus (HPV) co‐testing using physician‐, self‐, and urine‐collected samples to predict cervical intraepithelial neoplasia (CIN) grade 1–2 prognoses has not been previously reported. Therefore, this study aimed to investigate outcomes of patients with CIN 1–2 who simultaneously underwent physician‐, self‐, and urine‐collection sampling tests.MethodsThis study was conducted in Japan between October 2019 and November 2022 and examined the proportion of cases with CIN 1–2 progressions, the percentage of cases with persistent CIN 1–2, and the outcome differences according to the results of physician‐, self‐, and urine‐sampling tests.ResultsThere were 105 and 59 CIN 1 and 2 cases, respectively, with progression or persistence in 27 (29.3%) and 21 (50.0%) cases, respectively. The median follow‐up was 20 and 12 months, respectively. Progression and persistence of CIN 1 were significantly associated with HPV‐positive physician‐ and self‐collected samples. No significant difference was observed between cases with CIN 2 who had HPV‐positive and HPV‐negative results using any sampling method.ConclusionsPhysician‐ and self‐testing for HPV are crucial for predicting disease progression risk in CIN 1 cases. Future research with an extended observation period and consideration of the progression risks is warranted.

中文翻译：

---

人乳头瘤病毒自我取样和尿液取样检测以及宫颈上皮内瘤变的治疗和短期结果：一项前瞻性观察研究


目的 使用医生、自身和尿液采集的样本进行人乳头瘤病毒 (HPV) 联合检测来预测宫颈上皮内瘤变 (CIN) 1-2 级预后的重要性尚未有报道。因此，本研究旨在调查同时接受医生、自我和尿液采集采样检测的 CIN 1-2 患者的结果。 方法本研究于 2019 年 10 月至 2022 年 11 月在日本进行，检查了患有 CIN 1-2 的病例比例CIN 1-2 进展情况、持续性 CIN 1-2 病例的百分比，以及根据医生、自我检测和尿液取样检测结果得出的结果差异。结果 CIN 1 和 2 例分别为 105 例和 59 例，进展或持续的病例分别为 27 (29.3%) 和 21 (50.0%)。中位随访时间分别为 20 个月和 12 个月。 CIN 1 的进展和持续存在与 HPV 阳性医生和自行收集的样本显着相关。使用任何采样方法，HPV 阳性和 HPV 阴性结果的 CIN 2 病例之间没有观察到显着差异。 结论 医生和自我检测 HPV 对于预测 CIN 1 病例的疾病进展风险至关重要。未来的研究需要延长观察期并考虑进展风险。